NeuroDerm is a clinical-stage pharmaceutical company developing next-generation treatments for central nervous system (CNS) disorders that will make a clinically meaningful difference in patients’ lives. NeuroDerm’s technology enables new routes of administration for existing drugs that overcome their current deficiencies and achieve enhanced clinical efficacy.
NeuroDerm Announces First Quarter 2016 Financial Results
Company to Host Conference Call and Webcast Today at 8:30 a.m. ET ”> Read More
NeuroDerm to Host First Quarter 2016 Financial Results Conference Call on May 26, 2016
Management will host a conference call beginning at 8:30 a.m. Eastern Time that day to review results and provide a company update. ”> Read More
NeuroDerm Announces Patient Enrollment in Long-Term Safety Trial of ND0612 for Parkinson’s Disease
Trial to Provide Safety Data to Support U.S. and EU Regulatory Applications of Liquid Levodopa/Carbidopa Lead Product Candidate”> Read More